Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
The Phase III Krascendo 1 trial demonstrated that divarasib significantly improves progression-free and overall survival compared to existing KRAS G12C inhibitors.
Indication
Clinical and regulatory intelligence for KRAS G12C NSCLC with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.